U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07062588) titled 'Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)' on July 01.
Brief Summary: This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Osteogenesis Imperfecta (OI)
Intervention:
DRUG: AGA2115
Subcutaneous injection
OTHER: Placebo
Subcutaneous injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Angitia Incorporated Limited
Disclaimer: Curated by HT Syndication....